Talay Louis, Vickers Matt, Fuller Sarah
Faculty of Arts and Social Sciences, University of Sydney, Sydney, NSW 2050, Australia.
Eucalyptus, Sydney, NSW 2000, Australia.
Healthcare (Basel). 2024 Oct 21;12(20):2093. doi: 10.3390/healthcare12202093.
Digital weight loss services (DWLSs) that use Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated potential in contributing to a shift in global obesity rates. However, reasonable concerns have been raised about the prescribing safety of these services. Prior to this study, electronic prescribing safety had only been investigated in hospital settings and community clinics.
This study retrospectively analyzed prescribing errors committed over a 6-month period in 2023 at Australia's largest GLP-1 RA-supported DWLS.
The analysis found that 1654 (4.4%) of the 37323 audited GLP-1 RA prescriptions contained an error. Most errors pertained to insufficient safety counselling (49.15%) and inadequate investigations of potential contraindications (30.29%). Although a large portion of prescribing errors were detected via the automated query method (64.9%), the other three auditing methods all detected a significant number of true errors (>100). Patients from the highest body mass index category (40+ kg/m) were overrepresented in the service's prescribing error data.
These findings lay a vital foundation in the emerging literature on GLP-1 RA-supported DWLSs.
使用胰高血糖素样肽-1受体激动剂（GLP-1 RAs）的数字减肥服务（DWLSs）已显示出有助于全球肥胖率转变的潜力。然而，人们对这些服务的处方安全性提出了合理担忧。在本研究之前，电子处方安全性仅在医院环境和社区诊所中进行过调查。
本研究回顾性分析了2023年澳大利亚最大的GLP-1 RA支持的DWLS在6个月期间发生的处方错误。
分析发现，在37323份经审核的GLP-1 RA处方中，有1654份（4.4%）存在错误。大多数错误与安全咨询不足（49.15%）和对潜在禁忌症的调查不充分（30.29%）有关。虽然通过自动查询方法检测到了很大一部分处方错误（64.9%），但其他三种审核方法也都检测到了大量真实错误（>100）。在该服务的处方错误数据中，体重指数最高类别（40+kg/m）的患者占比过高。
这些发现为关于GLP-1 RA支持的DWLSs的新兴文献奠定了重要基础。
